DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) — MannKind Corporation MNKD will report its fourth quarter and full year 2022 financial results and management will host a conference call on Thursday, February 23, 2023 at 5:00 p.m. EST to discuss those results and company updates.

The company’s Chief Executive Officer, Michael Castagna, and Chief Financial Officer, Steven B. Binder will be present.

Those interested in listening to the conference call live over the Internet can do so by visiting the company’s website at mannkindcorp.com under Events & Presentations. A replay will be available on MannKin’s website for 14 days.

About MannKind
MannKind Corporation MNKD is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs in people living with endocrine and rare lung diseases.

We are committed to using our formulation skills and device development expertise to reduce the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry powder formulations and inhalers – provide fast and convenient delivery of drugs to the deep lungs, where they can act locally or enter the systemic circulation.

With a passionate team of Mannitarians working together nationwide, our mission is to give people control of their health and the freedom to live their lives.

please visit mannkindcorp.com to learn more and keep following us LinkedIn, Facebook, Twitter or Instagram.

man-child contact:
Rose Alinaya, Investor Relations
(818) 661-5000
E-mail: ir@mannkindcorp.com